{"name":"West German Study Group","slug":"west-german-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Myocet","genericName":"Myocet","slug":"myocet","indication":"Other","status":"phase_3"},{"name":"Trastuzumab Biosimilar ABP 980","genericName":"Trastuzumab Biosimilar ABP 980","slug":"trastuzumab-biosimilar-abp-980","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Standard-of-care endocrine treatment","genericName":"Standard-of-care endocrine treatment","slug":"standard-of-care-endocrine-treatment","indication":"Hormone receptor-positive breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"Myocet","genericName":"Myocet","slug":"myocet","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Standard-of-care endocrine treatment","genericName":"Standard-of-care endocrine treatment","slug":"standard-of-care-endocrine-treatment","phase":"phase_3","mechanism":"Blocks estrogen receptors to prevent cancer cell growth.","indications":["Hormone receptor-positive breast cancer"],"catalyst":""},{"name":"Trastuzumab Biosimilar ABP 980","genericName":"Trastuzumab Biosimilar ABP 980","slug":"trastuzumab-biosimilar-abp-980","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOeXE1SUh4OUFTRnN6TmtjMGtYZlliUDVic2VER2pHSXR0b0FldDE1OVRIbnBMYlNJTllpdHhkbG1mQjg0aGpNcWp4dHNsUW9YRjR2RUFLUlF6a0dsWWtOUndtLVI3eWh2QktwMW5jLU9ucVB6NHppVm9udkZrMUpmNlRFeUlYUVRRY0taRGRDVXR4V1Y5MHZWaQ?oc=5","date":"2025-12-03","type":"deal","source":"Politico","summary":"Lobbyists are salivating for more of Trump’s drug price deals - Politico","headline":"Lobbyists are salivating for more of Trump’s drug price deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPWmV0QkYyMUlGdUVkamJhMTF6d2Q2ak1FNlUtcUN4anVzZTRmd2lFa1VrRkhMTkdkNG11bUxrNjZ3TnBPak5ROFhQNGFucGhTT05KUTNld3JsNWdhVUtYVTRoWGhqcjZqZHF0WnZ5NTF4bmczM3FnM0pTU0tpb3ZVTGtyT3F1bnJkR2tYRnRpZFRvVUdmSVpZcVgzS1dsOUdiZ2o2Y3h4U04?oc=5","date":"2025-07-24","type":"pipeline","source":"International Finance Corporation (IFC)","summary":"Answering Africa’s Call for Private Investment in Pharma Manufacturing - International Finance Corporation (IFC)","headline":"Answering Africa’s Call for Private Investment in Pharma Manufacturing - International Finance Corporation (IFC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9qZEZPX2EtdTQ1UU1LMU1LNjU0c1JITDBOOU9pVlhFaEJqX1ZPTWdYcTlia0tiLW9yTDlUTTZTTVNKRWtlUDBMSFNBVGxvU3RlQkdkNi1HNGJvWmZUeENj?oc=5","date":"2025-02-25","type":"trial","source":"Nature","summary":"Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN) | Leukemia - Nature","headline":"Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNSmVZNjRrMXVzYklUUkp4RlByOTJydzJvd3RxT2V0WC1PaUFPN2ZlOU9hSTBpWUEtVDgtdFV6Qmw5UDEzcDBLSXlfRm0wWUlNUlpRM19XcmhZZmdwU19FVXFEMVYtcFdPOEM4UWlpN2x6WHRBLWRPODhjQThvcV9qZEl1R2toZ1VqNGZ1SmRiWV9WelljdDg0RWNuNExLSDVTV0lRQmlEQXhpcHlUMHJYX3d5VC1Ja1lNNVROSnpSVno?oc=5","date":"2024-12-19","type":"pipeline","source":"Oncology News Central","summary":"Comparison of Paclitaxel Regimens in Early Breast Cancer Raises Questions - Oncology News Central","headline":"Comparison of Paclitaxel Regimens in Early Breast Cancer Raises Questions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9nNVN3WHpWQ2puMERvV2lfTHV4TXR1RVpxZ29Cc2tnVUtZNEhsYktMdlpxZHUxbmIxX3RiVG5JX2E2WWdjcWV6bUl0Q2JqZ0RhRndfYzk1V1YxTGxT?oc=5","date":"2024-03-19","type":"trial","source":"EurekAlert!","summary":"New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status - EurekAlert!","headline":"New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5WdlpscXBJQlFUMXg5SzM3UHhsUWdpU3FXMWFRLUcxV2NfUkhIWG5pX2ttSTRGMEtLaUtPYVd5YXJ2MUFvTnp0TG53aU5yckl0YW9iRmlYTERGMTVrZGxTdnlpN01lVHkwNFE?oc=5","date":"2023-11-06","type":"trial","source":"Wiley Online Library","summary":"Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD) - Wiley Online Library","headline":"Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, globa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPU2xwR1FTTDA4UjBSYU1ZU05nXzFlaXZyM2pBQ0hJUWdGNjhEa2RmQ2pVcGprQ3Z6QjdHR0lkeExwemZUU0ZFS1h0RERYS3EtcXN2cThnZDRQMTBkZzIxdGdVTW9iMU8xSVdzdG40VE9wYURRY3lvRDI3Vkp0THJGV2xWclU2ZjZ4NF9v?oc=5","date":"2023-04-15","type":"trial","source":"The Lancet","summary":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials - The Lancet","headline":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFBxUVR6aU91a19CQkxDUFFEM2NMa2FFTkdFdVVndGpNUmZzcVJCQ0N6SXdDTTh5enJrT3NQS2FEV215clhVcWc4TmVMSWJPUklyTHpIY1B1dC0?oc=5","date":"2022-12-12","type":"trial","source":"ASCO Publications","summary":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial | Journal of Clin","headline":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5IVllhbjc1eGNNVmFHN2hzMy0wM29LYWg0MHNZTWNmTUtmUXREZ3VwQUVQQkVZbTJuZVJFTjI1V05nalZrSlV6dGhWSzJPeDFVdEFDb1BNZlJXalBaWDlDQWRLZzdHOU5uSHU3eHNRMHdaZw?oc=5","date":"2021-05-13","type":"pipeline","source":"Corporate Watch -","summary":"AstraZeneca: six scandals to remember - Corporate Watch -","headline":"AstraZeneca: six scandals to remember - Corporate Watch -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPeW9WMTdUbGpqY3Y5VWRNeF9tZVZ3eVZKVnNnWVF0aGw5Z3Z0TFNXR2d0NVBJc3BxNnA1WWFqM2gyLS1UQ3JqT04ybEZKRTJhX1BLNFBxeEdaVHN1Q29YWTNjSHpLYWwzeVpwa3ZHQ2RUUnZISlJsMEtmaUJscHN1MnA1UXdNUTlXSkNhQXFxNXVsSjJQVUFHUzczblB6XzVabmhlQmQ5Z05UbUVNRWxpU2JMYw?oc=5","date":"2021-02-11","type":"pipeline","source":"CancerNetwork","summary":"Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer - CancerNetwork","headline":"Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}